Patents by Inventor Gary J. Grover

Gary J. Grover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
    Patent number: 6916813
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts thereof, are useful for modulating mitochondrial F1F0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: July 12, 2005
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Karnail S. Atwal, Gary J. Grover, Charles Z. Ding, Philip D. Stein, John Lloyd, Saleem Ahmad, Lawrnce G. Hamann, David Green, Francis N. Ferrara
  • (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
    Publication number: 20040039033
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts thereof, 1
    Type: Application
    Filed: December 10, 2002
    Publication date: February 26, 2004
    Inventors: Karnail S. Atwal, Gary J. Grover, Charles Z. Ding, Philip D. Stein, John Lloyd, Saleem Ahmad, Lawrence G. Hamann, David Green, Francis N. Ferrara
  • Combination of a potassium channel activator and an antiarrhythmic agent
    Patent number: 5679706
    Abstract: A method for the concomitant treatment of ischemia and arrhythmia in mammalian species which includes administering a combination of a potassium channel opener having little or no effect on action potential duration in the heart and a class III antiarrhythmic compound.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: October 21, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. D'Alonzo, Gary J. Grover
  • Cardiopulmonary bypass and organ transplant using a potassium channel activator
    Patent number: 5643921
    Abstract: In accordance with the present invention novel methods for cardiopulmonary bypass and organ transplant, each employing a potassium channel activator, are disclosed. The use of a potassium channel activator has been found to reduce the damage or ischemia induced by the bypass and transplant procedures.
    Type: Grant
    Filed: September 26, 1990
    Date of Patent: July 1, 1997
    Assignee: E.R. Squibb & Sons, Inc.
    Inventor: Gary J. Grover
  • Method for inhibiting myocardial cell necrosis and preserving heart function during myocardial ischemia and/or reperfusion
    Patent number: 5354764
    Abstract: A method is provided for inhibiting myocardial cell necrosis and improving myocardial function during myocardial ischemia and/or reperfusion by locally administering to the heart a potent potassium channel activator such as pinacidil or cromakalim.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: October 11, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, Karnail Atwal
  • Method of treating or prevention of fibrillation of the heart
    Patent number: 5278169
    Abstract: A method for the treatment and prevention of fibrillation using one or more potassium channel activators. Also, disclosed is a process for the preparation of compounds of the formula ##STR1## and the tautomeric forms ##STR2## wherein R''and R" are as defined herein.
    Type: Grant
    Filed: July 9, 1990
    Date of Patent: January 11, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Karnail Atwal, Gary J. Grover
  • Method for inhibiting myocardial cell necrosis and preserving heart function during myocardial ischemia and/or reperfusion
    Patent number: 5256688
    Abstract: A method is provided for inhibiting myocardial cell necrosis and improving myocardial function during myocardial ischemia and/or reperfusion by locally administering to the heart a potent potassium channel activator such as pinacidil or cromakalim.
    Type: Grant
    Filed: October 29, 1991
    Date of Patent: October 26, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, Karnail Atwal
  • Pyranyl cyanoguanidine derivatives
    Patent number: 5140031
    Abstract: Novel compounds having the formula ##STR1## wherein ##STR2## are disclosed. These compounds have potassium channel activating activity and are useful, for example, as cardiovascular agents, especially as antiischemic agents.
    Type: Grant
    Filed: February 27, 1991
    Date of Patent: August 18, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Karnail Atwal, Gary J. Grover, Kyoung S. Kim
  • Pharmaceutical composition and method for treating cardiovascular diseases using substituted anilides and sulfonamides
    Patent number: 5116851
    Abstract: A novel pharmaceutical composition and method is disclosed for the treatment of cardiovascular diseases, e.g. myocardial ischemia and/or arrhythmia. The method and composition include an effective amount of a compound of the formula ##STR1## wherein X, Y, R, R.sub.1, A, A', m, n, p, p' and B are as defined herein.
    Type: Grant
    Filed: January 26, 1990
    Date of Patent: May 26, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: John Krapcho, James L. Bergey, Gary J. Grover
  • Method of preventing or reducing adverse reactions to protamine using a thromboxane A.sub.2 receptor antagonist
    Patent number: 5066480
    Abstract: A method is provided for preventing reducing or reversing adverse reactions, such as pulmonary hypertension produced when protamine interacts with heparin, by administering a thromboxane A.sub.2 receptor antagonist.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: November 19, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Martin L. Ogletree, William A. Schumacher, Gary J. Grover, Lawrence T. Friedhoff
  • Aryl cyanoguanidines: potassium channel activators and method of making same
    Patent number: 5011837
    Abstract: Novel compounds of the formula ##STR1## and tautomers thereof, wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is a strong electron withdrawing group, are disclosed. These compounds possess potassium channel activating activity and, as such, are useful as antihypertensive agents. Advantageously, the compounds of the present invention have shown less cardiac effects than known potassium channel activators.Also disclosed is a process for preparing these and other compounds.
    Type: Grant
    Filed: May 8, 1989
    Date of Patent: April 30, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Karnail Atwal, John R. McCullough, Gary J. Grover
  • Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
    Patent number: 5008284
    Abstract: Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-pro line or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre- and post-ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: April 16, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, James L. Bergey
  • Method of improving post-ischemic myocardial function using a thromboxane A2 antagonist in combination with a thrombolytic agent and combination
    Patent number: 4975279
    Abstract: A method is provided for improving post-ischemic myocardial function such as contractile dysfunction or reperfusion injury by administering a thromboxane receptor antagonist which is a 7-oxabicycloheptane substituted diamide prostaglandin analog in combination with a thrombolytic agent before, during or immediately after an ischemic attack.
    Type: Grant
    Filed: October 10, 1989
    Date of Patent: December 4, 1990
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: William A. Schumacher, Gary J. Grover
  • Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
    Patent number: 4962095
    Abstract: Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy (4-phenylbutyl) phosphinyl]oxy]-1-oxohexyl]-L-proline or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre-and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: October 9, 1990
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, James L. Bergey
  • Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
    Patent number: 4931464
    Abstract: Zofenopril, fosinopril, (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-oxohexyl]-L-proli ne or a pharmaceutically acceptable salt thereof alone or in combination with a thrombolytic, antiarrhythmic, or antifibrillatory agent is employed to reduce pre- and post- ischemic myocardial arrhythmias and fibrillations as well as reducing arrhythmias associated with congestive heart failure.
    Type: Grant
    Filed: February 15, 1989
    Date of Patent: June 5, 1990
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, James L. Bergey
  • Post-ischemic myocardial dysfunction using thromboxane A.sub.2 antagonists
    Patent number: 4931460
    Abstract: A method is provided for improving post-ischemic myocardial dysfunction such as contractile dysfunction or reperfusion injury by administering a thromboxane A.sub.2 antagonist before, during or immediately after an ischemic attack.
    Type: Grant
    Filed: September 17, 1987
    Date of Patent: June 5, 1990
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Gary J. Grover, Irvin E. Fulmor, III
  • Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A.sub.2 receptor antagonist
    Patent number: 4857548
    Abstract: A method is provided for preventing or reducing platelet loss during extracorporeal circulation, such as during coronary artery bypass of graft surgery by administering a thromboxane A.sub.2 antagonist alone or with prostacyclin and/or a prostacyclin mimic.
    Type: Grant
    Filed: November 17, 1988
    Date of Patent: August 15, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Gary J. Grover
  • Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A.sub.2 receptor antagonist
    Patent number: 4820733
    Abstract: A method is provided for preventing or reducing platelet loss during extracorporeal circulation, such as during coronary artery bypass or graft surgery by administering a thromboxane A.sub.2 antagonist alone or with prostacyclin and/or a prostacyclin mimic.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: April 11, 1989
    Assignee: E.R. Squibb & Sons, Inc.
    Inventor: Gary J. Grover
  • Combination of a calcium channel blocker and thromboxane A.sub.2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
    Patent number: H1139
    Abstract: A method is provided for treating ischemia in a mammalian species by administering a combination of a calcium channel blocker such as diltiazem, SQ 31,765 or SQ 32,324 and a thromoboxane A.sub.2 receptor antagonist such as SQ 30,741 or a thromboxane synthetase inhibitor such as dazoxiben.
    Type: Grant
    Filed: July 21, 1988
    Date of Patent: February 2, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Gary J. Grover